LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Titel:
LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Auteur:
Scherpereel, A. Antonia, S. Bautista, Y. Grossi, F. Kowalski, D. Zalcman, G. Nowak, A. Fujimoto, N. Peters, S. Tsao, A. Mansfield, A. Popat, S. Sun, X. Padilla, B. Aanur, P. Daumont, M. Bennett, B. McKenna, M. Baas, P.